## Appendix A

Workshop Agenda

Workshon	on Aguta	Chamical	Cafaty	Tostina	Annandix 1
worksnop	on Acute	Cnemicai	sajeiv	1 esting –	Appendix A

March 2009

[This Page Intentionally Left Blank]

# Workshop on Acute Chemical Safety Testing: Advancing In Vitro Approaches and Humane Endpoints for Systemic Toxicity Evaluations

#### National Institutes of Health (NIH) Natcher Conference Center

#### February 6 - 7,2008

#### **Workshop Agenda and Topics**

Day 1 Wednesday, February 6, 2008

0800 Registration

0830 Opening Session - Welcoming Remarks

William Stokes, D.V.M., D.A.C.L.A.M., Director NICEATM, Executive

Director, ICCVAM

Marilyn Wind, Ph.D., CPSC, Chair, ICCVAM

Thomas Hartung, M.D., Ph.D., Director, ECVAM

Hajime Kojima, Ph.D., Director, JaCVAM

#### **Workshop Objectives**

William Stokes, D.V.M., DACLAM

## Session 1 Acute Systemic Toxicity: Public Health Significance and Regulatory

**Testing Needs** 

Co-chairs: William Stokes, D.V.M., D.A.C.L.A.M. (NIEHS)

Marilyn Wind, Ph.D. (CPSC)

0900 Public Health Perspective of Acute Poisoning

Daniel Cobaugh, PharmD., DABAT, Director of Research and Program

Development, American Society of Health-System Pharmacists (ASHP)

Research and Education Foundation, Silver Spring, MD

0930 Regulatory Needs and Uses for Acute Systemic Toxicity Data

Amy Rispin, Ph.D., Senior Scientist, Field and External Affairs Division,

Office of Pesticide Programs, EPA

### Session 2 Acute Systemic Toxicity: Human and Animal Assessments, Biomarkers,

and Key Pathways

Co-Chairs: Debbie McCall (EPA)

Thomas Hartung, M.D., Ph.D. (ECVAM)

#### 0950 Data Currently Collected During Acute Systemic Toxicity Tests

Gary Wnorowski, B.A., M.B.A., LAT, President, Eurofins Product Safety

Labs

1010 Break

1030	Quantifying Evident Toxicity for the Fixed Dose Procedure Robert Guest, B.Sc., Head of Alternative and Acute Toxicology, SafePharm Laboratories			
1050	Clinical Biomarkers Used to Diagnose and Treat Acute Poisoning in Humans Frank Paloucek, Pharm.D. D.A.B.A.T., FASHP, Director of Residency Programs, College of Pharmacy, University of Illinois at Chicago			
1120	Clinical Biomarkers Used to Diagnose and Treat Acute Poisoning in Animals  Steven Hansen, D.V.M., D.A.B.T., D.A.B.V.T., Senior Vice President,  ASPCA Animal Poison Control Center, University of Illinois at Urbana-Champaign			
1150	Lunch			
1250	Methodologies for Collecting Clinical Biomarker Data in Laboratory Animals  Karen Steinmetz, Ph.D., D.A.B.T., Director, Mammalian Toxicology Dept.,  Biosciences Division, SRI International			
1310	Non-Invasive and Minimally Invasive Techniques for Measuring Physiological Parameters in Laboratory Rodents Kathleen Murray, D.V.M., M.S., D.A.C.L.A.M., Senior Director, Animal Program Management, Charles River Laboratories			
1335	Break			
1350	Concurrent Breakout Group Discussions  a. Breakout Group 1: Key Pathways for Acute Systemic Toxicity Co-chairs: Daniel Acosta, Ph.D., Dean, College of Pharmacy, University of Cincinnati Frank Paloucek, PharmD., D.A.B.A.T., FASHP, Director of Residency Programs, College of Pharmacy, University of Illinois at Chicago Recorders: David Allen, Ph.D., Integrated Laboratory Systems, Inc.			
	Raymond Tice, Ph.D., Deputy Director, NICEATM, NIEHS			
	b. Breakout Group 2: Current Acute Systemic Toxicity Injury and Toxicity Assessments			
	Co-chairs: A. Wallace Hayes, Ph.D., D.A.B.T., FATS, FlBiol, Science Advisor and Visiting Scientist, Harvard School of Public Health			

Systems, Inc

Recorders: Michael Paris, Integrated Laboratory Systems, Inc.

Daniel Marsman, D.V.M., Ph.D., D.A.B.T., Section Head, Animal Welfare and Alternatives, Procter & Gamble

Judy Strickland, Ph.D., D.A.B.T., Integrated Laboratory

1520	Break				
1535	<b>Concurrent Breakout Group Discussions (continued)</b>				
1700	Breakout Groups Adjourn				
1715	Breakout Group Co-chairs meet with Organizing Committee				
Close of Day	y 1				
Day 2	Thursday, February 7, 2008				
0800	Registration				
0830	Plenary Session - Discussion of Conclusions and Recommendations Reached by Breakout Groups 1 & 2 Co-Chairs: William Stokes, D.V.M., D.A.C.L.A.M., NIEHS/NICEATM Marilyn Wind, Ph.D., CPSC				
0830	a. <u>Breakout Group 1</u> : Key Pathways for Acute Systemic Toxicity Co-chairs: Daniel Acosta, Ph.D. Frank Paloucek, PharmD. D.A.B.A.T., FASHP				
0850	b. <u>Breakout Group 2</u> : Current Acute Systemic Toxicity Injury and Toxicity Assessments  Co-chairs: A. Wallace Hayes, Ph.D., D.A.B.T., FATS, FlBiol  Daniel Marsman, D.V.M., Ph.D., D.A.B.T.				
Session 3	Humane Endpoints Co-Chairs: Masih Hashim, Ph.D. (EPA) Cassandra Prioleau, Ph.D. (CPSC)				
0910	The Concept of Humane Endpoints and Their Identification: Application for Acute Systemic Toxicity Testing William Stokes, D.V.M., D.A.C.L.A.M., NIEHS, Director, NICEATM				
0930	Opportunities for Detecting Pain and Distress Associated with Acute Systemic Toxicity Steven Niemi, D.V.M., D.A.C.L.A.M., Director, Center for Comparative Medicine, Massachusetts General Hospital				
1000	Break				
Session 4	State of the Science: Using In Vitro Methods to Predict Acute Systemic Toxicity Co-Chairs: Steven Reynolds, Ph.D. (NIOSH) Hajime Kojima, Ph.D. (JaCVAM)				
1015	The Future of Toxicology as a Predictive Science Melvin Andersen, Ph.D., D.A.B.T., Director, Division of Computational Biology, The Hamner Institutes for Health Sciences				
1045	Recommendations from the ICCVAM-NICEATM International Workshop on <i>In Vitro</i> Methods for Assessing Acute Systemic Toxicity				

A.	Wallace Hayes,	Ph.D.,	D.A.B.T.,	FATS,	FlBiol,	Science	Advisor	and
	Visiting Scient	ist, Ha	rvard Scho	ol of Pu	ıblic He	alth		

- 1105 Current ICCVAM Recommendations for the Use of *In Vitro* Test
  Methods to Estimate Acute Systemic Toxicity
  Marilyn Wind, Ph.D., CPSC
- The ACuteTox Project: Optimization and Prevalidation of an *In Vitro*Test Strategy for Predicting Human Toxicity
  Thomas Hartung, M.D., Ph.D., Director, ECVAM
- 1145 Using High Throughput Screening (HTS) to Identify Predictive *In Vitro*Biomarkers for Acute Systemic Toxicity
  Raymond Tice, Ph.D., Deputy Director, NICEATM, NIEHS
- **1205** Lunch
- 1300 Concurrent Breakout Group Discussions
  - a. <u>Breakout Group 3</u>: Identifying Earlier Humane Endpoints for Acute Systemic Toxicity Testing

Co-chairs: Helen Diggs, D.V.M., M.Ed., SACATM member; Director, Office of Laboratory Animal Care, University of California, Berkeley

Steven Niemi, D.V.M., D.A.C.L.A.M., Director, Center for Comparative Medicine, Massachusetts General Hospital

Recorder: David Allen, Ph.D., Integrated Laboratory Systems, Inc.

b. <u>Breakout Group 4</u>: Application of *In Vivo* Mode of Action and Mechanistic Information to the Development and Validation of *In Vitro* Methods for Assessing Acute Systemic Toxicity

Co-chairs: Melvin Anderson, Ph.D., D.A.B.T., Director of the Division of Computational Biology, The Hamner Institutes for Health Sciences

Eugene Elmore, Ph.D., Project Scientist, Department of Radiation Oncology, University of California, Irvine

Recorder: Michael Paris, Integrated Laboratory Systems, Inc.

c. <u>Breakout Group 5</u>: Industry Involvement in Test Method Development, Validation, and Use

Co-chairs: Robert Scala, Ph.D., D.A.B.T., DATS, Consultant

William Stott, Ph.D., D.A.B.T., Senior Scientist, Toxicology and Environmental Research and Consulting, The Dow

Chemical Company

Recorder: Judy Strickland, Ph.D., D.A.B.T., Integrated Laboratory

Systems, Inc.

- 1420 Break
- 1435 Concurrent Breakout Group Discussions (continued)

1535 Break

1550 Plenary Session - Discussion of Conclusions and Recommendations Reached by the Breakout Groups

Co-Chairs: William Stokes, D.V.M., D.A.C.L.A.M., NIEHS/NICEATM Marilyn Wind, Ph.D., CPSC

a. <u>Breakout Group 3</u>: Humane Endpoints for Acute Systemic Toxicity Testing

Co-chairs: Helen Diggs, D.V.M., M.Ed., D.A.C.L.A.M. Steven Niemi, D.V.M., D.A.C.L.A.M.

b. Breakout Group 4: Application of *In Vivo* Mode of Action and Mechanistic Information to the Development and Validation of *In Vitro* Methods for Assessing Acute Systemic Toxicity

Co-chairs: Melvin Andersen, Ph.D., D.A.B.T. Eugene Elmore, Ph.D.

1630 c. <u>Breakout Group 5</u>: Industry Involvement in Test Method Development, Validation, and Use

Co-chairs: Robert Scala, Ph.D., D.A.B.T., D.A.T.S William Stott, Ph.D., D.A.B.T.

1650 Closing Comments

Marilyn Wind, Ph.D., CPSC, Chair, ICCVAM William Stokes, D.V.M., D.A.C.L.A.M., Director NICEATM, Executive Director, ICCVAM

1700 End of Meeting

Workshop on	Acuta	Chamical	Cafaty	Tagting	Annandiz /

March 2009

[This Page Intentionally Left Blank]